Document type
ArticleVersion
Published versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/218737
MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Objectives
To assess the clinical significance of myelin oligodendrocyte glycoprotein antibodies (MOG-abs)
restricted to CSF in children with inflammatory CNS disorders.
Methods
Patients included 760 children (younger than 18 years) from 3 multicenter prospective cohort
studies: (A) acquired demyelinating syndromes, including acute disseminated encephalomy-
elitis (ADEM); (B) non-ADEM encephalitis; and (C) noninflammatory neurologic disorders.
For all cases, paired serum/CSF samples were systematically examined using brain immuno-
histochemistry and live cell-based assays.
Results
A total of 109 patients (14%) had MOG-abs in serum or CSF: 79 from cohort A, 30 from B, and
none from C. Of these, 63 (58%) had antibodies in both samples, 37 (34%) only in serum, and 9
(8%) only in CSF. Children with MOG-abs only in CSF were older than those with MOG-abs
only in serum or in both samples (median 12 vs 6 vs 5 years, p = 0.0002) and were more likely to
have CSF oligoclonal bands (86% vs 12% vs 7%, p = 0.0001) and be diagnosed with multiple
sclerosis (6/9 [67%] vs 0/37 [0%] vs 1/63 [2%], p < 0.0001).
Discussion
Detection of MOG-abs in serum or CSF is associated with CNS inflammatory disorders.
Children with MOG-abs restricted to CSF are more likely to have CSF oligoclonal bands and
multiple sclerosis than those with MOG-abs detectable in serum.
Subject (English)
Citation
Citation
OLIVÉ CIRERA, Gemma, et al. MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders. Neurology. 2024. Vol. 102, num. 7. ISSN 0028-3878. [consulted: 6 of June of 2026]. Available at: https://hdl.handle.net/2445/218737